Baricitinib Improvement Across Regions in Atopic Dermatitis Patients with Baseline Body Surface Area up to 40% and Severe Itch José-Manuel CarrascosaAlessandra NarcisiAndreas Wollenberg Original Research Open access 22 May 2024
Biologics Versus JAK Inhibitors. Part I: Cancer Risk. A Narrative Review Miguel Mansilla-PoloDaniel Morgado-Carrasco Review Open access 19 May 2024
A Practical Approach to Diagnosing and Managing Chronic Spontaneous Urticaria Adam FriedmanShawn G. KwatraGil Yosipovitch Review Open access 17 May 2024
Evaluation of the Factors Influencing Mortality in Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Study of 166 Patients Funda ErduranEsra AdışenAkın Aktaş Original Research Open access 17 May 2024
Patient Burden of Nonsegmental Vitiligo: A US Real-World Survey of Dermatologists and Their Patients David RosmarinJennifer H. LoflandJinan Liu Original Research Open access 16 May 2024
Efficacy and Safety of Crisaborole Ointment 2% in Chinese Patients Aged ≥ 2 Years with Mild to Moderate Atopic Dermatitis Lin MaXiaohua TaoJianzhong Zhang Original Research Open access 15 May 2024 Pages: 1229 - 1243
Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis) Mario ValentiLuigi GargiuloAlessandra Narcisi Brief Report Open access 15 May 2024
Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience Federica Li PomiLucia PeterleFrancesco Borgia Case Series Open access 14 May 2024
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials Shawn G. KwatraSaakshi KhattriDennis McGonagle Original Research Open access 13 May 2024
Effects of 15% Azelaic Acid Gel in the Management of Post-Inflammatory Erythema and Post-Inflammatory Hyperpigmentation in Acne Vulgaris Huidi ShuchengXinyu ZhouXian Jiang Original Research Open access 11 May 2024 Pages: 1293 - 1314
Unmet Needs and Treatment Preference of Systemic Treatments for Moderate-to-Severe Psoriasis from the Perspectives of Patients and Dermatologists in China Yehong KuangYuzhen LiSteven Feldman Original Research Open access 11 May 2024 Pages: 1245 - 1257
Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis Mahek ShergillMuhammad Usman AliMohannad Abu-Hilal Review Open access 11 May 2024 Pages: 1093 - 1102
OPT-In; Optimized Patient Treatment Outcomes in Plaque Psoriasis: A 3-Year State-Transition Treatment-Sequencing Model in the Italian Setting Sarah AlulisNicoletta BernardiniFareen Hassan Original Research Open access 10 May 2024 Pages: 1273 - 1291
Real-World Long-Term Effectiveness of Risankizumab Among Patients with Moderate-to-Severe Psoriasis: Analysis from an International Medical Chart Review (RAPID) Study Andreas PinterAhmed M. SolimanMark Lebwohl Original Research Open access 10 May 2024 Pages: 1259 - 1271
Cutaneous Superficial Basal Cell Carcinoma is a Basal Cell Carcinoma In Situ: Electron Microscopy of a Case Series of Basal Cell Carcinomas Harsimran KaurKaren L. de Mesy BentleyBruce R. Smoller Case Series Open access 09 May 2024 Pages: 1359 - 1366
Brodalumab: 5-Year US Pharmacovigilance Report Mark G. LebwohlJohn Y. KooAbby A. Jacobson Brief Report Open access 09 May 2024 Pages: 1349 - 1357
Comparative Study on the Duration and Efficacy of Various Botulinum Toxin Type A Injections for Reducing Masseteric Muscle Bite Force and Treating Facial Wrinkles Surachet SirisuthivoranuntSupisara WongdamaRungsima Wanitphakdeedecha Original Research Open access 09 May 2024 Pages: 1315 - 1325
Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis Leon H. KircikLinda Stein GoldWilliam Philip Werschler Original Research Open access 09 May 2024 Pages: 1211 - 1227
High Intensity Focused Ultrasound (20 MHz) and Cryotherapy as Therapeutic Options for Granuloma Annulare and Other Inflammatory Skin Conditions Jacek CalikTomasz ZawadaTorsten Bove Original Research Open access 04 May 2024 Pages: 1189 - 1210
Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study Spyridon GkalpakiotisSusanna KannenbergIman Almasry Original Research Open access 04 May 2024 Pages: 1173 - 1187
Telemedicine in Nail Psoriasis: Validation of a New Tool to Monitor (In-Person, In-Picture, and In-Video) Nail Psoriasis Severity in Patients with Concurrent Onychophagia and Onychotillomania Alessia PacificoMatilde IorizzoGiovanni Damiani Original Research Open access 03 May 2024 Pages: 1161 - 1172
Lebrikizumab Provides Rapid Clinical Responses Across All Eczema Area and Severity Index Body Regions and Clinical Signs in Adolescents and Adults with Moderate-to-Severe Atopic Dermatitis Eric L. SimpsonMarjolein de Bruin-WellerJonathan I. Silverberg Original Research Open access 03 May 2024 Pages: 1145 - 1160
Topical and Systemic Retinoids in the Management of Hidradenitis Suppurativa: A Comprehensive Literature Review Elisa MolinelliHelena GioacchiniOriana Simonetti Review Open access 03 May 2024 Pages: 1079 - 1091
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2) Eric L. SimpsonVimal H. PrajapatiJonathan I. Silverberg Original Research Open access 02 May 2024 Pages: 1127 - 1144
Safety and Effectiveness of Percutaneous Ultrasound-Guided Galvanic Current in Tunnels of Patients with Hidradenitis Suppurativa: A Pilot Study Alberto Soto-MorenoCarlos Cuenca-BarralesAlejandro Molina-Leyva Original Research Open access 27 April 2024 Pages: 1115 - 1125
When Patient Diversity Informs Formulation: Reimagining Treatment for Seborrheic Dermatitis Meredith Tyree PolaskeyHeather Woolery-LlloydRaj Chovatiya Commentary Open access 27 April 2024 Pages: 1071 - 1077
Impact of Biologic Therapy on Key Cardiovascular Risk Parameters in a Psoriatic Cohort—a Retrospective Review Joseph JosephKelvin TruongAnnika Smith Brief Report Open access 25 April 2024 Pages: 1337 - 1348
Economic Burden of Itch-Related Sleep Loss in Moderate-to-Severe Atopic Dermatitis in the United Kingdom Evangeline J. PierceRussel T. BurgeYunni Yi Original Research Open access 23 April 2024 Pages: 1103 - 1114
Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month 12 for Patients with Moderate-to-Severe Plaque Psoriasis and Concomitant Nail Psoriasis Treated with Biologics from PSoHO Elisabeth RiedlAndreas PinterChristopher Schuster Brief Report Open access 22 April 2024 Pages: 1327 - 1335
Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60 Alexander EgebergJason E. HawkesApril Armstrong Original Research Open access 22 April 2024 Pages: 1007 - 1018
The Epidemiology of Hospital-Treated Alopecia Areata in Denmark, 1995–2016 Sissel Brandt Toft SørensenPrethibha GeorgeVera Ehrenstein Original Research Open access 16 April 2024 Pages: 993 - 1006
Matching-Adjusted Indirect Comparison of the Efficacy at Week 32 of Tralokinumab and Dupilumab in the Treatment of Moderate-to-Severe Atopic Dermatitis Tiago TorresAnne Sohrt PetersenJosé Manuel Carrascosa Original Research Open access 13 April 2024 Pages: 983 - 992
Novel Topical Treatments for Itch Rami H. MahmoudOmar MahmoudGil Yosipovitch Review Open access 13 April 2024 Pages: 829 - 840
Current Diagnostic and Therapeutic Practices in Alopecia Areata in Two Mediterranean Countries: A Survey-Based Study Michela StaraceFrancesca PampaloniZoe Apalla Original Research Open access 10 April 2024 Pages: 953 - 970
Publisher Correction to: Real-World Effectiveness of Dupilumab in Adult and Adolescent Patients with Atopic Dermatitis: 2-Year Interim Data from the PROSE Registry Eric L. SimpsonBen LockshinAndrew Korotzer Publisher Correction Open access 09 April 2024 Pages: 1367 - 1369
Letter to the Editor Regarding: Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study Ruiyao HuYue WangChen Li Letter Open access 09 April 2024 Pages: 1063 - 1065
Psoriasis and Molecular Target Therapies: Evidence of Efficacy in Preventing Cardiovascular Comorbidities Luca PotestioNello TommasinoMatteo Megna Review Open access 09 April 2024 Pages: 841 - 852
Response to: Letter to Editor Regarding “Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study” A. David Burden Letter Open access 05 April 2024 Pages: 1067 - 1069
Clinical Characteristics and Therapeutic Aspects of Blaschko Linear Psoriasis Ling ChenYufan ChengZhu Shen Brief Report Open access 05 April 2024 Pages: 1039 - 1048
Improvements in Psoriasis-Related Work Productivity with Tildrakizumab: Results from a Phase 4 Real-World Study in Patients with Moderate-to-Severe Plaque Psoriasis Tina BhutaniJohn KooJ. Gabriel Vasquez Brief Report Open access 04 April 2024 Pages: 1019 - 1025
Acute Systemic Toxicity Caused by Topical Application of EMLA Cream on a Leg Ulcer: Case Report and Review of Literature Sarah Marie HoffmannAnna Luisa HartmannChristoph Mathis Schempp Case Report Open access 03 April 2024 Pages: 1057 - 1062
Utilising SNP Association Analysis as a Prospective Approach for Personalising Androgenetic Alopecia Treatment Manuel Pacareu FrancèsLaura Vila-VecillaGustavo Torres de Souza Original Research Open access 31 March 2024 Pages: 971 - 981
Maintenance of Investigator’s Static Global Assessment Response with Once-Daily Crisaborole in Participants with Mild to Moderate Atopic Dermatitis Lawrence F. EichenfieldLinda F. Stein GoldJuliana M. Canosa Original Research Open access 28 March 2024 Pages: 875 - 892
Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study Ying LiChengzhi LvYuling Shi Original Research Open access 27 March 2024 Pages: 907 - 918
Virtual Learning Decreases the Carbon Footprint of Medical Education Divya SharmaJulianne RizzoJenny E. Murase Original Research Open access 26 March 2024 Pages: 853 - 859
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies April ArmstrongAlvaro González-CanteroAndrew Blauvelt Original Research Open access 23 March 2024 Pages: 933 - 952
Inconsistent Associations Between Risk Factor Profiles and Adjuvant Radiation Therapy (ART) Treatment in Patients with Cutaneous Squamous Cell Carcinoma and Utility of the 40-Gene Expression Profile to Refine ART Guidance Brent R. MoodyAaron S. FarbergWalton A. Taylor Original Research Open access 23 March 2024 Pages: 861 - 873
Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries Sergio Vañó-GalvánAlexander EgebergAnthony Bewley Brief Report Open access 21 March 2024 Pages: 1027 - 1037
Effect of Makeup Use on Depressive Symptoms: An Open, Randomized and Controlled Trial Marcos C. VeçosoSouvenir ZallaVânia R. Leite-Silva Original Research Open access 21 March 2024 Pages: 777 - 791
Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi Consensus Luigi GargiuloLuciano IbbaAlessandra Narcisi Original Research Open access 21 March 2024 Pages: 919 - 932